December 2, 2018 01:31 PM EST

#ASH18: Gilead posts impressive survival rates for Yescarta — but sales remain lean

John Carroll

Editor & Founder

A little more than a year after Yescarta was approved as the first CAR-T for third-line therapy in large B-cell lymphoma, researchers are still trying to determine what the median overall survival rate for patients is. It hasn’t been reached.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

#ASH18: Gilead posts impressive survival rates for Yescarta — but sales remain lean

John Carroll

Editor & Founder

Unlock this article instantly by becoming a free subscriber.

FDA rolls out long-awaited proposal to overhaul diagnostics regulation

In the race to get type 1 patients off insulin, focus turns to cell transplants and insulin-producing stem cells

FDA unveils new rare disease pilot program to increase agency-sponsor communications

Despite a summer of blockbuster rounds, biotech funding is on track to level off at pre-pandemic norms

Madrigal raises $500M for NASH drug launch, discloses cyberattack

CMIC: Japan’s first and largest CRO continues 30-year evolution to help global sponsors navigate the complex local ...

#ASH18: Gilead posts im­pres­sive sur­vival rates for Yescar­ta — but sales re­main lean

John Carroll

Editor & Founder

Unlock this article instantly by becoming a free subscriber.

FDA rolls out long-await­ed pro­pos­al to over­haul di­ag­nos­tics reg­u­la­tion

In the race to get type 1 pa­tients off in­sulin, fo­cus turns to cell trans­plants and in­sulin-pro­duc­ing stem cells

FDA un­veils new rare dis­ease pi­lot pro­gram to in­crease agency-spon­sor com­mu­ni­ca­tions

De­spite a sum­mer of block­buster rounds, biotech fund­ing is on track to lev­el off at pre-pan­dem­ic norms

Madri­gal rais­es $500M for NASH drug launch, dis­clos­es cy­ber­at­tack

CMIC: Japan’s first and largest CRO con­tin­ues 30-year evo­lu­tion to help glob­al spon­sors nav­i­gate the com­plex lo­cal ...

#ASH18: Gilead posts impressive survival rates for Yescarta — but sales remain lean

FDA rolls out long-awaited proposal to overhaul diagnostics regulation

In the race to get type 1 patients off insulin, focus turns to cell transplants and insulin-producing stem cells

FDA unveils new rare disease pilot program to increase agency-sponsor communications

Despite a summer of blockbuster rounds, biotech funding is on track to level off at pre-pandemic norms

Madrigal raises $500M for NASH drug launch, discloses cyberattack

CMIC: Japan’s first and largest CRO continues 30-year evolution to help global sponsors navigate the complex local ...